Elicio Therapeutics Prices $15M Registered Direct Offering at Discount to Market
ELTX sits 56% above its 52-week low of $2.66.
Summary
Elicio Therapeutics announced the pricing of a $15 million registered direct offering at $3.43 per share, a discount to its current stock price, to fund clinical development and operations.
Key Events · Financing and Capital Events · ELTX
-
Registered Direct Offering Priced
Elicio Therapeutics finalized the terms of a registered direct offering, agreeing to sell 4,380,313 shares of common stock to institutional investors at an offering price of $3.43 per share, raising approximately $15 million in gross proceeds. This follows the S-3 shelf registration filed on February 27, 2026.
-
Significant Discount to Market
The offering price of $3.43 per share represents a substantial discount compared to the current market price of $4.16, indicating the urgency of the capital raise.
-
Critical Capital for Operations
The proceeds are earmarked for funding planned Phase 1 clinical development of ELI-002 7P and general working capital, which is vital given the company's 'going concern' warning and recent Phase 2 trial setback.
-
30-Day Lock-Up Period
The company has agreed to a 30-day restriction on issuing additional common stock or equivalents, providing a temporary stabilization period post-offering.
Analysis · ELTX · Life Sciences
Elicio Therapeutics finalized the terms of a registered direct offering, securing $15 million by selling 4.38 million shares at $3.43 each, a notable discount to the current market price. This capital raise is critical for the company, which has a 'going concern' warning and recently reported a Phase 2 trial miss. The proceeds will fund clinical development and general working capital, extending the company's cash runway. While highly dilutive for existing shareholders, this financing provides essential liquidity for continued operations.
At the time of this filing, ELTX was trading at $4.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.1M. The 52-week trading range was $2.66 to $16.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.